Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach HbA1c targets at roughly half the rate of non-carriers when treated with GLP-1 therapy. For the 38 million Americans living with Type 2 diabetes — and the millions more taking GLP-1s for weight loss — this is being framed as the first precision-medicine breakthrough for the GLP-1 era. It is — for understanding why these drugs fail for some patients. It is not, and cannot be, a reversal.
What Just Happened
The Stanford-led study, published in 2026, identified specific variants in the PAM (peptidyl-glycine alpha-amidating monooxygenase) gene that cause a phenomenon researchers are calling “GLP-1 resistance” — where patients have higher circulating GLP-1 hormone levels but the hormone is less biologically effective, as detailed in the Stanford Bio-X highlight.
The headline numbers from the Stanford Medicine News report, Stanford Bio-X, and Science Daily coverage:
- Population affected: Roughly 10% of the general population carry specific variants in the PAM gene, with the two key variants being p.S539W and p.D563G, per the Stanford Medicine News report.
- What GLP-1 resistance means: These individuals have higher circulating GLP-1 hormone levels, but GLP-1 is less biologically effective — a phenomenon termed GLP-1 resistance, per the MedCentral analysis.
- Clinical impact in Type 2 diabetes: A meta-analysis of three trials (1,119 participants with T2D) showed about 25% of non-carriers reached recommended HbA1c targets after 6 months of GLP-1 RA treatment, versus only 11.5% of p.S539W carriers and 18.5% of p.D563G carriers — a meaningful reduction in drug effectiveness, per the Stanford Medicine News report.
- Specificity to GLP-1 drugs: The reduced response was specific to GLP-1 receptor agonists; carriers did not respond differently to metformin, sulfonylureas, or DPP-4 inhibitors, per Science Daily coverage and the Stanford Diabetes Research Center.
- Mechanism: PAM is an enzyme that activates many peptide hormones, including GLP-1. The variants reduce PAM activity, leading to altered GLP-1 processing and a need for “more GLP-1 to get the same biological effect,” per the MedCentral analysis.
The Question Nobody’s Asking
Here’s what every headline about the Stanford GLP-1 resistance findings is leaving out: understanding why a drug fails for some patients still doesn’t reverse the disease for anyone.
Stanford just identified a genetic reason why GLP-1s don’t work for 1 in 10 people. That’s a real scientific
advance — it will eventually lead to better patient selection, companion diagnostics, and personalized prescribing. But the underlying framework remains the same: take the drug, lower the A1c while you’re on it, watch the A1c climb back when you stop. The insulin resistance never gets addressed. The beta-cell dysfunction never gets addressed. The medication overrides the symptom — or, for 1 in 10 patients, fails to even do that — while the disease keeps running the show.
That’s not a flaw in the science. It’s the entire treatment paradigm. Every GLP-1 on the market — injectable or
oral, effective or genetically resistant — is a lifelong lease on disease management, not a deed to remission. A
precision-medicine breakthrough that helps doctors pick the right drug is a real win. But “better drug selection” and “reversal of Type 2 diabetes” are two completely different games.
So the real question for the millions of Americans taking — or considering — a GLP-1 isn’t “will this drug work for me genetically?” It’s “why am I still diabetic in the first place, and what’s actually required to reverse it?”
What Reversal Actually Looks Like
At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — off every diabetes medication — sustained. Not “controlled.” Not “managed.” Reversed.
Our patients hit reversal in an average of 4.5 months — the time to get the attached results, within the 5 month
average from the independent study. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), validated by an independent study of 137 participants (2013–2021) showing an average post-program A1c of 6.04%, average time in program of 4.5 months.
The Bottom Line
Stanford just found why GLP-1s don’t work for 1 in 10 people. It’s a real win for precision medicine. A system that reverses the disease is a different game entirely — one genetics alone cannot fix.
If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to look at what’s actually possible. Watch our free webinar — the same presentation our medical team uses with
new patients.
By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group / Kristine Burke, MD / Chief Medical
Officer / Diabetes Reversal Group. The only patented system in the world proven to reverse Type 2 diabetes.